Epigenica, founded in 2020 and based in Solna, Sweden, is a pioneering life-science company that has developed the EpiFinder™ platform—a high-throughput, multiplexed ChIP-seq solution that simultaneously profiles DNA methylation and histone modifications across multiple samples. Powered by its proprietary hmqChIP-seq and barcoding technology, EpiFinder enables researchers to generate up to 192 genome-wide epigenetic profiles in a single workflow, using minimal input material. This scalable, cost-effective approach breaks through traditional barriers of epigenetic analysis and supports applications in drug discovery, precision medicine, oncology, and longevity research. With strong investor backing, Epigenica is expanding its product line and infrastructure to serve global markets, including the U.S., while building a suite of kits and services designed to enable large-scale epigenomic studies.